Acitretin, a systemic retinoid prescribed for severe psoriasis and related skin conditions, presents a legitimate airworthiness concern for certificated pilots beyond simply checking whether the drug appears on a prohibited substances list. The pilot's framing of the question reflects a widespread misconception: the FAA does not maintain a simple binary "banned or approved" medication registry. Instead, the regulatory framework governing flight fitness on medication involves two overlapping considerations — whether the underlying medical condition is itself disqualifying, and whether the prescribed medication produces side effects incompatible with safe flight operations. Acitretin is known to cause night vision impairment (reduced dark adaptation, a function of retinoid metabolism in the retina), dry eyes, and photosensitivity, all of which carry direct implications for cockpit performance regardless of whether flying occurs at night.
The regulatory anchor for this situation is 14 CFR 61.53, which prohibits a pilot from acting as pilot in command or required flight crewmember when the pilot knows or has reason to know of any medical condition that would prevent meeting the standards for their medical certificate. Critically, this standard applies to daytime VFR operations just as much as night flying. Dry eyes can impair instrument scanning and visual acuity; photosensitivity can create glare intolerance that degrades situational awareness; and even subtle deficits in night adaptation can compromise safety in unlit traffic pattern environments or when transiting twilight conditions. The intent to avoid night flying during the two-month treatment is a reasonable precaution, but it does not resolve the full scope of physiological risk.
The commonly cited "48-hour rule" is a rule of thumb — not an FAA regulation — that has been propagated informally within the pilot community as a conservative minimum waiting period before flying after starting a new medication. It has no codified standing in the FARs. The operationally sound practice is to assess whether any side effects are present before any flight, not simply to observe an arbitrary delay. For a drug like acitretin with systemic metabolic effects that can persist throughout the entire course of treatment, the wait-and-evaluate approach must be ongoing, not a one-time clearance after the initial 48 hours. Pilots should document their self-assessment process and err toward grounding when symptoms are ambiguous.
Consulting an Aviation Medical Examiner before beginning a two-month course of acitretin is strongly advisable and represents best practice for any airman with a current medical certificate. AMEs are positioned to evaluate the clinical context of the underlying skin condition — some dermatological diagnoses do carry reportable status — and can provide guidance on whether the medication requires FAA AMCD notification or a special issuance evaluation. AOPA's Pilot Protection Services and the FAA's MedXPress system offer supplemental resources, but they do not substitute for the individualized clinical judgment an AME can apply. For commercial operators, Part 135 certificate holders, and airline pilots operating under Part 121, the stakes are elevated further: chief pilots and flight operations departments typically require documented AME consultation before a crewmember returns to line flying after initiating any medication with known sensory or cognitive side effects.
The confusion this pilot articulates is symptomatic of a broader gap in pilot education around aeromedical self-certification. Unlike other aviation regulatory domains, medication fitness involves ongoing self-assessment under a legal obligation where the pilot bears the certification burden. The FAA's aviation safety program materials and AME community have been working to improve accessible guidance on this topic, but the practical reality is that many general aviation pilots do not encounter medication questions until they actually need them — precisely the situation this pilot describes. For operators of any complexity, establishing a proactive relationship with an AME before a medical issue arises produces far better outcomes than reactive consultation during a course of treatment. The correct sequence here is AME first, medication start second, with a frank clinical discussion about the scope of flying planned, the severity of potential side effects, and any reporting obligations that may attach to the underlying condition.